| Patent application number | Description | Published |
|---|
| 20080292695 | CARVEDILOL FORMS, COMPOSITIONS, AND METHODS OF PREPARATION THEREOF - Disclosed are amorphous carvedilol salt forms, controlled-release carvedilol compositions, and methods of preparing the forms and compositions. | 11-27-2008 |
| 20090028935 | CARVEDILOL FORMS, COMPOSITIONS, AND METHODS OF PREPARATION THEREOF - Disclosed are amorphous carvedilol salt forms, controlled-release carvedilol compositions, and methods of preparing the forms and compositions. | 01-29-2009 |
| 20090263478 | CARVEDILOL FORMS, COMPOSITIONS, AND METHODS OF PREPARATION THEREOF - Disclosed are amorphous carvedilol salt forms, controlled-release carvedilol compositions, and methods of preparing the forms and compositions. | 10-22-2009 |
| 20100092556 | ALFUZOSIN FORMULATIONS, METHODS OF MAKING, AND METHODS OF USE - Alfuzosin compositions comprising a tablet core of alfuzosin and a release-retarding matrix comprising about 40 to about 80% (by weight) hydroxypropyl methyl cellulose with a maximum apparent viscosity of about 5600 cP, based on the total weight of the tablet core; and an extended-release coating substantially surrounding the tablet core comprising a release-retarding coating material, wherein the compositions are bioequivalent to the reference dosage form of NDA #021287 (UROXATRAL) are disclosed. Methods of making and using the alfuzosin compositions are also disclosed. | 04-15-2010 |
| 20100159009 | CONTROLLED-RELEASE FORMULATIONS - Disclosed herein are extended-release levetiracetam formulations having a matrix comprising levetiracetam and a hydrophobic excipient or an acrylic polymer excipient. | 06-24-2010 |
| 20100172979 | CONTROLLED-RELEASE FORMULATIONS - Disclosed herein are controlled-release formulations containing a core comprising a core active agent (e.g., levetiracetam) and a wax excipient, where the core is substantially coated with an extended-release coating. | 07-08-2010 |
| 20100183717 | CONTROLLED-RELEASE FORMULATIONS - Disclosed herein are controlled-release formulations of a core comprising a core active agent (e.g., alfuzosin) and a wax excipient substantially coated with an extended-release coating. | 07-22-2010 |
| 20110150986 | QUININE FORMULATIONS, METHOD OF MAKING, AND METHO OF USE THEREOF - Disclosed herein are quinine formulations and methods of using quinine formulations. Specifically disclosed herein are solid oral dosage forms which can be administered as a capsule or tablet, or alternatively as a sprinkle form with the patient experiencing little or no bitter taste. The dosage forms provide immediate release in vitro and in vivo. | 06-23-2011 |
| 20110150992 | QUININE FORMULATIONS, METHOD OF MAKING, AND METHOD OF USE THEREOF - Disclosed herein are quinine formulations and methods of using quinine formulations. Specifically disclosed herein are solid oral dosage forms which can be administered as a capsule or tablet, or alternatively as a sprinkle form with the patient experiencing little or no bitter taste. The dosage forms provide immediate release in vitro and in vivo. | 06-23-2011 |
